SYDNEY, Dec. 10, 2015 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) a clinical-stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), today announced that the Company will host a conference call and live audio webcast on Tuesday, December 15, 2015, at 4:30 pm ET/ Wednesday, December 16, at 8.30am AEST, to provide an operational update. Interim CEO, Greg West will provide an overview of Benitec's current and planned corporate and clinical activities.
Conference Call and Webcast Information:
Interested participants and investors may access the conference call and Q&A by dialing either +1 877 870-4263 (U.S.) or +1 412-317-0790 (International), and request to join the Benitec Biopharma conference call. Investors can also access a live, audio webcast link at https://www.webcaster4.com/Webcast/Page/1346/12373 to hear the update. It is recommended investors dial in or log on five minutes before the the call commences.
An archive of the webcast will remain available on Benitec's website for 90 days beginning at approximately 5:30 pm, ET on December 15, 2015.
For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com
Head of Investor Relations &
Tel: +61 (2) 9555 6986
PCG Advisory Group
Managing Director of Investor Relations
Tel: + 1 646-862-4607
Managing Director of Public Relations
Tel: +1 646-863-8998
About Benitec Biopharma Limited:
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward, CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.
Safe Harbor Statement:
This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Benitec has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to Benitec's pipeline of ddRNAi-based therapeutics, including the initiation, progress and outcomes of clinical trials and any other statements that are not historical facts. Such forward-looking statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to the difficulties or delays in our plans to develop and potentially commercialize our product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, potential future out-licenses and collaborations, our intellectual property position and duration of our patent portfolio, the ability to procure additional sources of financing and other risks detailed from time to time in filings that Benitec makes with US Securities and Exchange Commission, including our most recent annual report on Form 20-F and our reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
SOURCE Benitec Biopharma Limited